[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 30, 1967

Simulated Abuse of Tybamate in Man: Failure to Demonstrate Withdrawal Reactions

Author Affiliations

From the Veterans Administration Hospital, Palo Alto, Calif.

JAMA. 1967;199(5):338-340. doi:10.1001/jama.1967.03120050080022

TYBAMATE is a chemical analogue of meprobamate which shares many of the pharmacological properties of the latter drug (Figure). These properties include sedative, anticonvulsant, and musclerelaxant effects. Tybamate differs from meprobamate in that it reverses the electroencephalographic activation produced by lysergic acid diethylamide tartrate (LSD-25) in rabbits, antagonizes the rise in blood pressure induced by serotonin in dogs, and is extensively bound to protein.1 A number of clinical reports, including some double-blind comparisons with placebo and meprobamate, attest to its clinical efficacy.2,3 Despite considerable clinical use, so far no instances of withdrawal reactions have been encountered. Early investigations suggested freedom from withdrawal effects. Even when administered over a long period of time to dogs in doses of 570 mg/kg of body weight; no withdrawal seizures were encountered; dogs treated with comparable doses of meprobamate had frequent withdrawal seizures, often fatal.4

As canine withdrawal reactions have correlated well